 CHARLOTTESVILLE, Va., June 30, 2021 GLOBE NEWSWIRE -- Acumen Pharmaceuticals, Inc. Acumen or Acumen Pharmaceuticals Nasdaq: ABOS, a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimers disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of 16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately 160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. 